3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
102
Carcinoma, Intraductal, Noninfiltrating
12
Breast Carcinoma In Situ
10
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms, Male
6
Neoplasms
5
Glioblastoma
5
Central Nervous System Neoplasms
5
Prostatic Neoplasms
4
Gliosarcoma
4
Inflammatory Breast Neoplasms
3
Glioma
3
Brain Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Breast Cancer Female
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Risk Reduction Behavior
1
Interventions
bazedoxifene
1
Tamoxifen
1
Estrogens, Conjugated (USP)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Risk Reduction Behavior
×
Tamoxifen
×
Clear all
NCT03346200
2025-03-07
KARISMA2
Karolinska Institutet
Phase 2
Completed
1,440 enrolled
14 charts